Saint A, Evesque L, Falk AT, et al. - In this retrospective analysis, researchers assessed progression-free survival (PFS) as well as overall survival (OS), response rate, and toxicity in patients with metastatic squamous cell carcinomas (SCC) of the anal canal who were treated with 5-Fluorouracil (5-FU) and mitomycin after the failure of platinum-based regimen. A median of three cycles (1-7) of mitomycin 5-FU was administered to 19 patients with a median age of 57 years. In 6 patients (31.6%), a dose reduction was a must, and cessation of therapy due to toxicity was reported in one patient. No death because of treatment toxicity was documented. Five patients had an objective response. Median PFS was 3 months and median OS was 7 months. Overall, tumor control with acceptable tolerance was achieved with mitomycin and 5-FU regimen. This treatment regimen affords a choice in the treatment of patients with metastatic SCC of the anal canal following failure of platinum-based chemotherapy.